CAS 943319-70-8 appears in our catalog under these names: Ponatinib, Ponatinib, >95% (HPLC), Ponatinib (AP24534), Ponatinib, 98+%, Ponatinib, 98.00%. Offered by: Chemat Brand, TRC, GLPBio, Biosynth, Thermo Scientific (Acros). Available pack sizes: on request, 10mg, 1mg, 25mg, 100mg, 5mg, 10mM (in 1ml dmso), 50mg.
Ponatinib is a benzamide obtained by the formal condensation of the carboxy group of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylbenzoic acid with the anilino group of 4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)aniline. It is a multi-target tyrosine kinase inhibitor that targets ABL, SRC, FGFR, and others and was designed to overcome the resistance of BCR-ABL mutation to imatinib, in particular the gatekeeper mutation ABLT315I. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is a member of benzamides, a N-methylpiperazine, an imidazopyridazine, an acetylenic compound and a member of (trifluoromethyl)benzenes. It is a conjugate base of a ponatinib(1+).
Source: ChEBI
| Molecular formula | C29H27F3N6O |
|---|---|
| Molecular weight | 532.6 g/mol |
| IUPAC name | 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide |
| InChIKey | PHXJVRSECIGDHY-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5 |
Computed by PubChem (NCBI)